已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The impact of occlusion therapy and predictors on amblyopia dose–response relationship

医学 闭塞 视力 回顾性队列研究 眼科 儿科 外科
作者
Emily White,Leah Walsh
出处
期刊:Strabismus [Taylor & Francis]
卷期号:30 (2): 78-89 被引量:1
标识
DOI:10.1080/09273972.2022.2046114
摘要

This study aimed to calculate the dose-response relationship and predictors of visual acuity (VA) improvement following occlusion therapy at the IWK Health Center Eye Clinic and to add to amblyopia therapy dose-response relationship literature. A retrospective chart review was performed, considering patients who reached an occlusion therapy outcome at the IWK Eye Clinic between 2012 and 2019. The treatment outcome was defined as equal VA or stable VA for three consecutive clinical visits despite reported compliance. Subjective patching hours from parental reports, not prescribed hours, were used for statistical analyses. One hundred and thirty-four patients (66 females and 68 males) ages 2-11 years were included. Results showed a dose-response relationship of 224 hours/0.1logMAR increase in VA and total dose of 1344 hours for full-time occlusion and 504 hours for part-time occlusion was required to reach outcome VA. The fastest VA improvement occurred with younger age at treatment initiation, during the first 4 weeks of treatment, and in patients with strabismic and/or severe amblyopia. Classification of amblyopia, age, VA chart, initial distance VA (amblyopic eye), and treatment dose predicted the hour dose-response relationship. Dose-response relationship was faster in younger participants, in participants with strabismic and severe amblyopia, and during the first month of occlusion. Additionally, by creating a GLM model of dose-response relationship, relationship calculations can be performed. Therefore, an estimated timeline can be developed to allow allocation of clinical resources and to prepare patients for the treatment duration required and possibly increase treatment compliance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
睿O宝宝O发布了新的文献求助10
刚刚
赘婿应助追寻的饼干采纳,获得10
刚刚
3秒前
4秒前
二柱子完成签到 ,获得积分10
6秒前
ami关闭了ami文献求助
7秒前
fedehe完成签到 ,获得积分10
7秒前
可爱航发布了新的文献求助10
7秒前
科研通AI6.1应助zz采纳,获得10
8秒前
9秒前
10秒前
10秒前
10秒前
科研通AI6.2应助Andyvictory采纳,获得10
11秒前
chenwenjun发布了新的文献求助10
14秒前
16秒前
BBF3发布了新的文献求助10
16秒前
19秒前
无极微光应助废柴采纳,获得20
22秒前
cdercder应助微S采纳,获得10
22秒前
dudu88完成签到 ,获得积分10
24秒前
缥缈绮兰发布了新的文献求助10
24秒前
专注的夜雪完成签到,获得积分10
26秒前
Hello应助静汉采纳,获得10
28秒前
研友_LMyRPL发布了新的文献求助10
28秒前
Feixay完成签到 ,获得积分10
28秒前
29秒前
Eina完成签到,获得积分10
31秒前
Shirley完成签到 ,获得积分10
32秒前
molihuakai应助wzc采纳,获得10
33秒前
深情安青应助Lily采纳,获得10
33秒前
可爱航完成签到 ,获得积分10
36秒前
37秒前
刘Boyce发布了新的文献求助10
37秒前
37秒前
38秒前
Jodie发布了新的文献求助50
38秒前
Fighting完成签到 ,获得积分10
39秒前
DKJ应助张教授采纳,获得10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Elgar Concise Encyclopedia of Space Law 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6944221
求助须知:如何正确求助?哪些是违规求助? 8629728
关于积分的说明 18305354
捐赠科研通 6379282
什么是DOI,文献DOI怎么找? 3079195
关于科研通互助平台的介绍 2120003
邀请新用户注册赠送积分活动 2056076